- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02282397
Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes (DIaMonD)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study design includes two cohorts that will be treated separately. Phase 1 will include two diabetes cohorts (Type 1 diabetes mellitus and Type 2 diabetes mellitus) who will be randomized independently into two groups, Group 1-CGM and Group 2-SMBG.
The Group-1 CGM cohort who have Type 1 diabetes mellitus will be eligible for Phase 2. Phase 2 will include a separate independent randomization of either MDI therapy (Group 1a- CGM/MDI) or CSII therapy (Group 1b-CGM/CSII).
Additional assessments will be made to evaluate the incremental benefits of changing the insulin delivery method from MDI to CSII in patients already using CGM.
Cost effectiveness and quality of life will be measured between the two groups in each phase.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Barrie, Ontario, Canada, L4M 7G1
- LMC Clinical Research
-
Thornhill, Ontario, Canada, L4J 8L7
- LMC Clinical Research
-
Toronto, Ontario, Canada, M4G 3E8
- LMC Clinical Research
-
-
-
-
California
-
Greenbrae, California, United States, 94904
- Marin Endocrine Care & Research
-
Ventura, California, United States, 93003
- Coastal Metabolic Research Centre
-
-
Florida
-
Jacksonville, Florida, United States, 32216
- East Coast Institute for Research, LLC
-
Jacksonville, Florida, United States, 32204
- East Coast Institute for Research, LLC
-
-
Georgia
-
Atlanta, Georgia, United States, 30318
- Atlanta Diabetes Associates
-
Atlanta, Georgia, United States, 30308
- Laureate Medical Group at Northside, LLC
-
Columbus, Georgia, United States, 31904
- Columbus Regional Research Institute
-
Lawrenceville, Georgia, United States, 30046
- Physicians Research Associates, LLC
-
Roswell, Georgia, United States, 30076
- Endocrine Research Solutions
-
-
Idaho
-
Idaho Falls, Idaho, United States, 83404
- Rocky Mountain Diabetes & Osteoporosis Center
-
-
Iowa
-
Des Moines, Iowa, United States, 50314
- Iowa Diabetes & Endocrinology Research Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Joslin Diabetes Center
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Health System
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55416
- International Diabetes Center
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University in St. Louis
-
-
Nebraska
-
Omaha, Nebraska, United States, 68114
- Diabetes & Endocrine Associates, PC
-
-
Nevada
-
Las Vegas, Nevada, United States, 89106
- Accent Clinical Research
-
-
New York
-
Albany, New York, United States, 12206
- Albany Medical College
-
-
North Carolina
-
Asheville, North Carolina, United States, 28803
- Mountain Diabetes and Endocrine Center
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
Portland, Oregon, United States, 97225
- Legacy Research Institute
-
-
Texas
-
Amarillo, Texas, United States, 79106
- Amarillo Medical Specialists, LLP
-
Dallas, Texas, United States, 75231
- Research Institute Of Dallas
-
San Antonio, Texas, United States, 78229
- Diabetes and Glandular Disease
-
San Antonio, Texas, United States, 78258
- Consano Clinical Research
-
-
Utah
-
Ogden, Utah, United States, 84405
- Advanced Research Associates
-
Riverton, Utah, United States, 84065
- Granger Medical Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 25 years or older
- Diagnosis of Type 1 diabetes mellitus or insulin-requiring Type 2 diabetes mellitus
- Followed regularly by a physician or diabetes educator
- Using multiple daily injections
- stable control of diabetes
- willing to wear a device such as pump or continuous glucose monitor
Exclusion Criteria:
- recent or planned use of non-insulin injectable hypoglycemic agents
- Pregnancy or planning to become pregnant during the study
- Medical conditions that make it inappropriate or unsafe to target an A1C of <7%
- Renal disease with Glomerular Filtration Rate <45
- Extensive skin changes/disease that precludes wearing the sensor on normal skin
- Known allergy to medical-grade adhesives
- Recent hospitalization or emergency room visit in the 6 months prior to screening resulting in primary diagnosis of uncontrolled diabetes
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Phase 1: SMBG
Type 1 or Type 2 diabetes mellitus subjects using SMBG testing and usual care for diabetes management.
No intervention to be administered
|
|
Other: Phase 1: CGM
Type 1 or Type 2 diabetes mellitus subjects using RT-CGM and SMBG testing for diabetes management.
RT-CGM (Continuous Glucose Monitoring) is the intervention.
|
RT-CGM are adjunctive devices with glucose trend graphs and user-configurable low and high glucose alerts.
Other Names:
|
No Intervention: Phase 2: CGM/MDI
Type 1 Diabetes Mellitus subjects using RT-CGM and injections for diabetes management.
|
|
No Intervention: Phase 2: CGM/CSII
Type 1 Diabetes Mellitus subjects using RT-CGM and CSII for diabetes management.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1 (T1DM) - A1C
Time Frame: 6 months
|
Change in A1C from baseline to 24 weeks
|
6 months
|
Phase 1 (T2DM) - A1C
Time Frame: 6 months
|
Change in A1C from baseline to 24 weeks
|
6 months
|
Phase 2 (T1DM)
Time Frame: 6 months
|
Change in % time in range 70-180 mg/dL from Phase 2 baseline to Phase 2 28 weeks
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1 (T1DM) - A1C Outcomes
Time Frame: 6 months
|
% of subjects with A1C less than 7%
|
6 months
|
Phase 1 (T1DM) - A1C Outcomes
Time Frame: 6 months
|
% of subjects with A1C less than 7.5%
|
6 months
|
Phase 1 (T1DM) - A1C Outcomes
Time Frame: 6 months
|
% of subjects with a relative reduction in A1C greater than or equal to 10%
|
6 months
|
Phase 1 (T1DM) - A1C Outcomes
Time Frame: 6 months
|
% of subjects with a reduction in A1C greater than or equal to 1%
|
6 months
|
Phase 1 (T1DM) - A1C Outcomes
Time Frame: 6 months
|
% of subjects with a reduction in A1C greater than or equal to 1% or A1C less than 7%
|
6 months
|
Phase 1 (T1DM) - CGM Outcomes
Time Frame: 6 months
|
Mean glucose (overall, daytime, and nighttime separately)
|
6 months
|
Phase 1 (T1DM) - CGM Outcomes
Time Frame: 6 months
|
Glucose variability (overall, daytime, and nighttime separately)
|
6 months
|
Phase 1 (T1DM) - CGM Outcomes
Time Frame: 6 months
|
% time in range 70-180 mg/dL (overall, daytime, and nighttime separately)
|
6 months
|
Phase 1 (T1DM) - CGM Outcomes
Time Frame: 6 months
|
% time less than 70 mg/dL (overall, daytime, and nighttime separately)
|
6 months
|
Phase 1 (T1DM) - CGM Outcomes
Time Frame: 6 months
|
% time less than 60 mg/dL (overall, daytime, and nighttime separately)
|
6 months
|
Phase 1 (T1DM) - CGM Outcomes
Time Frame: 6 months
|
% time less than 50 mg/dL (overall, daytime, and nighttime separately)
|
6 months
|
Phase 1 (T1DM) - CGM Outcomes
Time Frame: 6 months
|
% time greater than 180 mg/dL (overall, daytime, and nighttime separately)
|
6 months
|
Phase 1 (T1DM) - CGM Outcomes
Time Frame: 6 months
|
% time greater than 250 mg/dL (overall, daytime, and nighttime separately)
|
6 months
|
Phase 1 (T1DM) - CGM Outcomes
Time Frame: 6 months
|
% time greater than 300 mg/dL (overall, daytime, and nighttime separately)
|
6 months
|
Phase 1 (T1DM) - Hypoglycemia Awareness
Time Frame: 6 months
|
Change in Clarke Hypoglycemia Unawareness score from baseline to 24 weeks
|
6 months
|
Phase 1 (T1DM) - SMBG Outcome
Time Frame: 6 months
|
Change in SMBG frequency from baseline to 24 weeks
|
6 months
|
Phase 1 (T1DM) - QoL Outcomes
Time Frame: 6 months
|
Quality of life changes from baseline to 24 weeks
|
6 months
|
Phase 1 (T1DM) - Cost Effectiveness
Time Frame: 6 months
|
Cost effectiveness measured by the incremental cost-effectiveness ratio (ICER)
|
6 months
|
Phase 1 (T1DM) - Adverse Events
Time Frame: 6 months
|
Change in the number of SH events from baseline to 24 weeks
|
6 months
|
Phase 1 (T1DM) - Adverse Events
Time Frame: 6 months
|
Change in the number of DKA events from baseline to 24 weeks
|
6 months
|
Phase 1 (T1DM) - Body Weight
Time Frame: 6 months
|
Change in body weight from baseline to 24 weeks
|
6 months
|
Phase 1 (T1DM) - Insulin Use Outcomes
Time Frame: 6 months
|
Change in total daily insulin from baseline to 24 weeks
|
6 months
|
Phase 1 (T1DM) - Insulin Use Outcomes
Time Frame: 6 months
|
Basal to bolus insulin ratio
|
6 months
|
Phase 1 (T1DM) - Insulin Use Outcomes
Time Frame: 6 months
|
Change in the number of boluses/day from baseline to 24 weeks
|
6 months
|
Phase 1 (T2DM) - A1C Outcomes
Time Frame: 6 months
|
% of subjects with A1C less than 7%
|
6 months
|
Phase 1 (T2DM) - A1C Outcomes
Time Frame: 6 months
|
% of subjects with A1C less than 7.5%
|
6 months
|
Phase 1 (T2DM) - A1C Outcomes
Time Frame: 6 months
|
% of subjects with a relative reduction in A1C greater than or equal to 10%
|
6 months
|
Phase 1 (T2DM) - A1C Outcomes
Time Frame: 6 months
|
% of subjects with a reduction in A1C greater than or equal to 1% or A1C less than 7%
|
6 months
|
Phase 1 (T2DM) - A1C Outcomes
Time Frame: 6 months
|
% of subjects with a reduction in A1C greater than or equal to 1%
|
6 months
|
Phase 1 (T2DM) - CGM Outcomes
Time Frame: 6 months
|
Mean glucose (overall, daytime, and nighttime separately)
|
6 months
|
Phase 1 (T2DM) - CGM Outcomes
Time Frame: 6 months
|
Glucose variability (overall, daytime, and nighttime separately)
|
6 months
|
Phase 1 (T2DM) - CGM Outcomes
Time Frame: 6 months
|
% time in range 70-180 mg/dL (overall, daytime, and nighttime separately)
|
6 months
|
Phase 1 (T2DM) - CGM Outcomes
Time Frame: 6 months
|
% time less than 70 mg/dL (overall, daytime, and nighttime separately)
|
6 months
|
Phase 1 (T2DM) - CGM Outcomes
Time Frame: 6 months
|
% time less than 60 mg/dL (overall, daytime, and nighttime separately)
|
6 months
|
Phase 1 (T2DM) - CGM Outcomes
Time Frame: 6 months
|
% time less than 50 mg/dL (overall, daytime, and nighttime separately)
|
6 months
|
Phase 1 (T2DM) - CGM Outcomes
Time Frame: 6 months
|
% time greater than 180 mg/dL (overall, daytime, and nighttime separately)
|
6 months
|
Phase 1 (T2DM) - CGM Outcomes
Time Frame: 6 months
|
% time greater than 250 mg/dL (overall, daytime, and nighttime separately)
|
6 months
|
Phase 1 (T2DM) - CGM Outcomes
Time Frame: 6 months
|
% time greater than 300 mg/dL (overall, daytime, and nighttime separately)
|
6 months
|
Phase 1 (T2DM) - CGM Outcomes
Time Frame: 6 months
|
Area above curve 70 mg/dL (overall, daytime, and nighttime separately)
|
6 months
|
Phase 1 (T2DM) - CGM Outcomes
Time Frame: 6 months
|
Area under curve 180 mg/dL (overall, daytime, and nighttime separately)
|
6 months
|
Phase 1 (T2DM) - Hypoglycemia Awareness
Time Frame: 6 months
|
Change in Clarke Hypoglycemia Unawareness score from baseline to 24 weeks
|
6 months
|
Phase 1 (T2DM) - SMBG
Time Frame: 6 months
|
Change in SMBG frequency from baseline to 24 weeks
|
6 months
|
Phase 1 (T2DM) - QoL Outcomes
Time Frame: 6 months
|
Quality of life changes from baseline to 24 weeks
|
6 months
|
Phase 1 (T2DM) - Cost Effectiveness
Time Frame: 6 months
|
Cost effectiveness measured by the incremental cost-effectiveness ratio (ICER)
|
6 months
|
Phase 1 (T2DM) - Adverse Events
Time Frame: 6 months
|
Change in the number of SH Events from baseline to 24 weeks
|
6 months
|
Phase 1 (T2DM) - Adverse Events
Time Frame: 6 months
|
Change in the number of DKA Events from baseline to 24 weeks
|
6 months
|
Phase 1 (T2DM) - Body Weight
Time Frame: 6 months
|
Change in body weight from baseline to 24 weeks
|
6 months
|
Phase 1 (T2DM) - Insulin Use Outcomes
Time Frame: 6 months
|
Change in total daily insulin from baseline to 24 weeks
|
6 months
|
Phase 1 (T2DM) - Insulin Use Outcomes
Time Frame: 6 months
|
Basal to bolus insulin ratio
|
6 months
|
Phase 1 (T2DM) - Insulin Use Outcomes
Time Frame: 6 months
|
Change in the number of boluses/day from baseline to 24 weeks
|
6 months
|
Phase 2 (T1DM) - A1C Outcomes
Time Frame: 6 months
|
Change in A1C from Phase 2 baseline to Phase 2 28 weeks
|
6 months
|
Phase 2 (T1DM) - A1C Outcomes
Time Frame: 6 months
|
% of subjects with A1C less than 7%
|
6 months
|
Phase 2 (T1DM) - A1C Outcomes
Time Frame: 6 months
|
% of subjects with A1C less than 7.5%
|
6 months
|
Phase 2 (T1DM) - A1C Outcomes
Time Frame: 6 months
|
% of subjects with a relative reduction in A1C greater than or equal to 10%
|
6 months
|
Phase 2 (T1DM) - A1C Outcomes
Time Frame: 6 months
|
% of subjects with a reduction in A1C greater than or equal to 1%
|
6 months
|
Phase 2 (T1DM) - A1C Outcomes
Time Frame: 6 months
|
% of subjects with a reduction in A1C greater than or equal to 1% or A1C less than 7%
|
6 months
|
Phase 2 (T1DM) - CGM Outcomes
Time Frame: 6 months
|
Mean glucose (overall, daytime, and nighttime separately)
|
6 months
|
Phase 2 (T1DM) - CGM Outcomes
Time Frame: 6 months
|
Glucose variability (overall, daytime, and nighttime separately)
|
6 months
|
Phase 2 (T1DM) - CGM Outcomes
Time Frame: 6 months
|
% time less than 70 mg/dL (overall, daytime, and nighttime separately)
|
6 months
|
Phase 2 (T1DM) - CGM Outcomes
Time Frame: 6 months
|
% time less than 60 mg/dL (overall, daytime, and nighttime separately)
|
6 months
|
Phase 2 (T1DM) - CGM Outcomes
Time Frame: 6 months
|
% time less than 50 mg/dL (overall, daytime, and nighttime separately)
|
6 months
|
Phase 2 (T1DM) - CGM Outcomes
Time Frame: 6 months
|
% time greater than 180 mg/dL (overall, daytime, and nighttime separately)
|
6 months
|
Phase 2 (T1DM) - CGM Outcomes
Time Frame: 6 months
|
% time greater than 250 mg/dL (overall, daytime, and nighttime separately)
|
6 months
|
Phase 2 (T1DM) - CGM Outcomes
Time Frame: 6 months
|
% time greater than 300 mg/dL (overall, daytime, and nighttime separately)
|
6 months
|
Phase 2 (T1DM) - CGM Outcomes
Time Frame: 6 months
|
Area above curve 70 mg/dL (overall, daytime, and nighttime separately)
|
6 months
|
Phase 2 (T1DM) - CGM Outcomes
Time Frame: 6 months
|
Area above curve 180 mg/dL (overall, daytime, and nighttime separately)
|
6 months
|
Phase 2 (T1DM) - Hypoglycemia Awareness
Time Frame: 6 months
|
Change in Clarke Hypoglycemia Unawareness score from Phase 2 baseline to Phase 2 28 weeks
|
6 months
|
Phase 2 (T1DM) - CGM Use
Time Frame: 6 months
|
Change in frequency of CGM use from Phase 2 baseline to Phase 2 28 weeks
|
6 months
|
Phase 2 (T1DM) - SMBG
Time Frame: 6 months
|
Change in SMBG frequency from Phase 2 baseline to Phase 2 28 weeks
|
6 months
|
Phase 2 (T1DM) - QoL Outcomes
Time Frame: 6 months
|
Quality of life changes from Phase 2 baseline to Phase 2 28 weeks
|
6 months
|
Phase 2 (T1DM) - Cost Effectiveness
Time Frame: 6 months
|
Cost effectiveness measured by the incremental cost-effectiveness ratio (ICER)
|
6 months
|
Phase 2 (T1DM) - Adverse Events
Time Frame: 6 months
|
Change in the number of SH Events from Phase 2 baseline to Phase 2 28 weeks
|
6 months
|
Phase 2 (T1DM) - Adverse Events
Time Frame: 6 months
|
Change in the number of DKA Events from Phase 2 baseline to Phase 2 28 weeks
|
6 months
|
Phase 2 (T1DM) - Body Weight
Time Frame: 6 months
|
Change in body weight from Phase 2 baseline to Phase 2 28 weeks
|
6 months
|
Phase 2 (T1DM) - Insulin Use Outcomes
Time Frame: 6 months
|
Change in total daily insulin from Phase 2 baseline to Phase 2 28 weeks
|
6 months
|
Phase 2 (T1DM) - Insulin Use Outcomes
Time Frame: 6 months
|
Basal to bolus insulin ratio
|
6 months
|
Phase 2 (T1DM) - Insulin Use Outcomes
Time Frame: 6 months
|
Change in the number of boluses/day from Phase 2 baseline to Phase 2 28 weeks
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1 (T1DM) - Post-Hoc CGM Outcomes
Time Frame: 6 months
|
Area above curve 70 mg/dL (overall, daytime, and nighttime separately)
|
6 months
|
Phase 1 (T1DM) - Post-Hoc CGM Outcomes
Time Frame: 6 months
|
Area under curve 180 mg/dL (overall, daytime, and nighttime separately)
|
6 months
|
Phase 1 (T2DM) - Post-Hoc A1C Outcome
Time Frame: 6 months
|
% of subjects with a reduction in A1C greater than or equal to 0.5%
|
6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: David Price, MD, DexCom, Inc.
Publications and helpful links
General Publications
- Hermanns N, Ehrmann D, Heinemann L, Freckmann G, Waldenmaier D, Calhoun P. Real-Time Continuous Glucose Monitoring Can Predict Severe Hypoglycemia in People with Type 1 Diabetes: Combined Analysis of the HypoDE and DIAMOND Trials. Diabetes Technol Ther. 2022 Sep;24(9):603-610. doi: 10.1089/dia.2022.0130. Epub 2022 Jun 10.
- Puhr S, Welsh JB, Bauza CE, Walker TC. Patients with Type 2 Diabetes and Residual Insulin Secretory Capacity Realize Glycemic Benefits from Real-Time Continuous Glucose Monitoring. J Diabetes Sci Technol. 2021 Jul;15(4):965-967. doi: 10.1177/19322968211007880. Epub 2021 Apr 15. No abstract available.
- Calhoun P, Price D, Beck RW. Glycemic Improvement Using Continuous Glucose Monitoring by Baseline Time in Range: Subgroup Analyses from the DIAMOND Type 1 Diabetes Study. Diabetes Technol Ther. 2021 Mar;23(3):230-233. doi: 10.1089/dia.2020.0471. Epub 2020 Oct 20.
- Puhr S, Calhoun P, Welsh JB, Walker TC. The Effect of Reduced Self-Monitored Blood Glucose Testing After Adoption of Continuous Glucose Monitoring on Hemoglobin A1c and Time in Range. Diabetes Technol Ther. 2018 Aug;20(8):557-560. doi: 10.1089/dia.2018.0134. Epub 2018 Jul 23.
- Beck RW, Riddlesworth TD, Ruedy K, Ahmann A, Haller S, Kruger D, McGill JB, Polonsky W, Price D, Aronoff S, Aronson R, Toschi E, Kollman C, Bergenstal R; DIAMOND Study Group. Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial. Ann Intern Med. 2017 Sep 19;167(6):365-374. doi: 10.7326/M16-2855. Epub 2017 Aug 22.
- Beck RW, Riddlesworth TD, Ruedy KJ, Kollman C, Ahmann AJ, Bergenstal RM, Bhargava A, Bode BW, Haller S, Kruger DF, McGill JB, Polonsky W, Price D, Toschi E; DIAMOND Study Group. Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2017 Sep;5(9):700-708. doi: 10.1016/S2213-8587(17)30217-6. Epub 2017 Jul 12.
- Riddlesworth T, Price D, Cohen N, Beck RW. Hypoglycemic Event Frequency and the Effect of Continuous Glucose Monitoring in Adults with Type 1 Diabetes Using Multiple Daily Insulin Injections. Diabetes Ther. 2017 Aug;8(4):947-951. doi: 10.1007/s13300-017-0281-4. Epub 2017 Jun 14.
- Polonsky WH, Hessler D, Ruedy KJ, Beck RW; DIAMOND Study Group. The Impact of Continuous Glucose Monitoring on Markers of Quality of Life in Adults With Type 1 Diabetes: Further Findings From the DIAMOND Randomized Clinical Trial. Diabetes Care. 2017 Jun;40(6):736-741. doi: 10.2337/dc17-0133. Epub 2017 Apr 7.
- Beck RW, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S, Kollman C, Kruger D, McGill JB, Polonsky W, Toschi E, Wolpert H, Price D; DIAMOND Study Group. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 2017 Jan 24;317(4):371-378. doi: 10.1001/jama.2016.19975.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PTL-901148
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Active, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Joslin Diabetes CenterCambridge Medical Technologies, LLCCompletedType 2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
Clinical Trials on Continuous Glucose Monitor
-
Yale UniversityMedtronicWithdrawn
-
University of NebraskaGreat Plains IDeA-CTREnrolling by invitationType 2 DiabetesUnited States
-
University of California, Los AngelesRecruitingPediatric ObesityUnited States
-
University of WashingtonDexCom, Inc.RecruitingGestational DiabetesUnited States
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Denver Health and Hospital AuthorityEnrolling by invitationAvoidant Restrictive Food Intake Disorder | Anorexia Nervosa, Binge Eating/Purging Type | ARFID | Anorexia Nervosa Restricting TypeUnited States
-
University of VirginiaDexCom, Inc.CompletedDiabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1United States
-
Hamilton Health Sciences CorporationThoma, Achilleas; Jiayi Hu; Matthew McRaeUnknown
-
HealthPartners InstituteThe Leona M. and Harry B. Helmsley Charitable TrustCompletedType 1 DiabetesUnited States
-
Woman'sDexCom, Inc.Active, not recruitingGestational Diabetes Mellitus in PregnancyUnited States